Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,521 signal articles · 30 in last 24h · 122,251 total before filter · latest 25m ago
30last 24h
1259last 7d
213● bullish (7d)
150● bearish (7d)
205publishers
AllMacro211Earnings431M&A96Regulatory23Product9Analyst11
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Raymond James says Dell Technologies Inc. (DELL) Termination Earnings effect on Arrow ‘likely immaterial’
Insider Monkey45d agoneutral
Raymond James says Dell Technologies Inc. (DELL) Termination Earnings effect on Arrow ‘likely immaterial’

Dell Technologies Inc. (NYSE:DELL) is among the Best Stocks To Buy. On June 2, Raymond James said the market may be overstating the financial impact of Dell Technologies Inc. (NYSE:DELL)’s decision to end its Enterprise Computing Distribution agreement with Arrow Electronics. The firm maintained an Outperform rating on Arrow. Analyst Melissa Fairbanks said the contract’s […]

F5 (FFIV) Stock Looks Cheap On Cash Flow But Pricey On Earnings
Simply Wall St.45d agoneutral
F5 (FFIV) Stock Looks Cheap On Cash Flow But Pricey On Earnings

F5 stock has delivered a strong 180.5% return over the past three years, yet its valuation checks are sending mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating the shares may trade below intrinsic value while market multiples point the other way. Over three years, F5 has returned 180.5%, which puts extra attention on whether recent gains already reflect the company’s long term cash flow potential. Recent earnings strength and the partnership with Equinix...

Abbott Laboratories (ABT) Q1 Sales And Guidance Put Fair Value Back In Focus
Simply Wall St.45d agoneutral
Abbott Laboratories (ABT) Q1 Sales And Guidance Put Fair Value Back In Focus

Abbott Laboratories (ABT) is back in focus after reporting Q1 2026 sales of US$11.16b with solid contributions from Medical Devices and issuing full year guidance that points to mid single digit comparable sales growth. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares have picked up short term momentum, with a 7 day share price return of 5.62% and a 30 day share price return of 5.24%. This sits against a year to date share price decline of 22.83% and a 1 year total...

CAVA Group (CAVA) Could Be 6% Overvalued Ahead Of Earnings
Simply Wall St.45d agoneutral
CAVA Group (CAVA) Could Be 6% Overvalued Ahead Of Earnings

Recent Stock Weakness and Earnings Anticipation CAVA Group (CAVA) has recently seen its stock decline and lag the broader market and its sector, as investors turn attention to the company’s upcoming earnings report and what it may imply for future performance. See our latest analysis for CAVA Group. At a share price of $69.74, CAVA Group’s short term momentum has cooled, with the share price down 3.02% over one day and 11.14% over seven days. Its year to date share price return of 15.18%...

Huntington Ingalls Industries (HII) Stock Looks Cheap On Cash Flow And Earnings
Simply Wall St.45d agoneutral
Huntington Ingalls Industries (HII) Stock Looks Cheap On Cash Flow And Earnings

Huntington Ingalls Industries stock has returned 59.2% over the past five years, yet current valuation work, including a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples, both point to the shares trading at a discount to what the fundamentals suggest. Over the past 5 years, Huntington Ingalls Industries has delivered a 59.2% return, which still leaves the stock screening as undervalued on intrinsic value and market multiple checks. Recent contract wins in unmanned...